Overview

Tocladesine in Treating Patients With Recurrent or Refractory Multiple Myeloma

Status:
Completed
Trial end date:
1999-11-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of tocladesine in treating patients who have recurrent or refractory multiple myeloma.
Phase:
Phase 2
Details
Lead Sponsor:
Northwestern University
Collaborator:
National Cancer Institute (NCI)
Treatments:
8-chloro-cyclic adenosine monophosphate